KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Current Assets (2017 - 2025)

Moderna (MRNA) has disclosed Current Assets for 9 consecutive years, with $6.5 billion as the latest value for Q4 2025.

  • Quarterly Current Assets fell 19.2% to $6.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.5 billion through Dec 2025, down 19.2% year-over-year, with the annual reading at $6.5 billion for FY2025, 19.2% down from the prior year.
  • Current Assets for Q4 2025 was $6.5 billion at Moderna, down from $6.6 billion in the prior quarter.
  • The five-year high for Current Assets was $16.4 billion in Q1 2022, with the low at $6.2 billion in Q2 2025.
  • Average Current Assets over 5 years is $10.8 billion, with a median of $10.7 billion recorded in 2023.
  • The sharpest move saw Current Assets soared 836.29% in 2021, then tumbled 36.12% in 2025.
  • Over 5 years, Current Assets stood at $16.1 billion in 2021, then fell by 16.43% to $13.4 billion in 2022, then decreased by 23.13% to $10.3 billion in 2023, then fell by 21.56% to $8.1 billion in 2024, then fell by 19.2% to $6.5 billion in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $6.5 billion, $6.6 billion, and $6.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.